Maruho Receives Manufacturing and Marketing Approval for Blood-flow Accelerative/Skin-moisturizing Agent "Hirudoid® Foam 0.3%"
Osaka (Japan), February 16, 2018 - Maruho Co., Ltd ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces that on February 15, 2018, blood-flow accelerative/skin-moisturizing agent "Hirudoid® Foam 0.3%" (INN: heparinoid, hereinafter referred to as "the product"), received manufacturing and marketing approval in Japan as an additional formulation.
In general, it is known that adherence to topical treatments is poorer than to oral treatments*1. Moreover, the clinical efficacy of moisturizing agents in topical treatments varies depending on the number of applications*2.
The product is a foam agent (topical aerosol agent) that ejects fine-grained foam from the container and contains the same active ingredients in the same concentration as "Hirudoid®" products currently available. The product is easily spread and can be quickly applied to a wide range of affected areas. Maruho hopes the product will expand treatment options and improve adherence for patients suffering from asteatosis and other skin diseases.
Maruho will continue to promote the proper use of the product and approved prescription drug "Hirudoid®" products to contribute to patients suffering from skin diseases.
Product profile: Hirudoid® Foam 0.3%
| INN | Heparinoid |
| Formulation/Dose | Topical aerosol containing 3.0mg of heparinoid per 1 gram |
| Indication | Thrombophlebitis (including hemorrhoids), Pain and inflammatory diseases owing to circulatory disturbance (induration and pain after injection), Chilblain, Treatment and prevention of hypertrophic scar or keloid, Keratodermia tylodes palmaris progressiva, Asteatosis, Swelling, hematoma, tendosynovitis, myalgia, arthritis after trauma (bruise, sprain, and/or contusion), Torticollis muscularis (infant) |
| Dosage and Administration |
Usually, apply an appropriate amount of the product to the affected area once to several times a day. |